ANAB Stock — AnaptysBio, Inc.

AnaptysBio, Inc. (ANAB)

Updated October 16, 2026.

ANAB is a Stock. Total return is 311.3% over the past 9.7 years, 23.9 points ahead of SPY at 287.4%.

AnaptysBio is a clinical-stage biotechnology company developing immunology therapeutics for autoimmune and inflammatory diseases, with a pipeline including candidates for rheumatoid arthritis, celiac disease, eosinophilic esophagitis, solid tumors, and generalized pustular psoriasis, alongside partnerships with GSK and Vanda. The company does not currently have an established distribution schedule. This security appeals to investors seeking exposure to early-stage biotech development with the associated risks of clinical-stage drug candidates.

ANAB performance versus SPY

Price and return data through 2026-10-16.

Total return is 311.3% over the past 9.7 years, 23.9 points ahead of SPY at 287.4%. Over the past year its total return — price change plus distributions reinvested — is 103.2%. Its deepest 1-year drawdown was 34.7%.

ANAB key facts

Asset type

Stock

Asset class

Equity

Inception date

01/26/2017

Distribution frequency

None

Last close

$46.61 (as of 2026-10-16)

Market cap

$1,393,417,323

Average volume

413635.0

Beta

0.452

Payout ratio

0.0%

Forward P/E

21.0084

EPS

$-0.96

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ANAB risks and drawbacks

The deepest 1-year drawdown on record here is 34.7%.

Who may consider ANAB — and who may not

It is a weaker fit for investors who need monthly cash flow (ANAB does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on ANAB

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions